Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266

Watchlist Manager
Suzhou Zelgen Biopharmaceuticals Co Ltd Logo
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Watchlist
Price: 64.04 CNY -4.28% Market Closed
Market Cap: 17B CNY
Have any thoughts about
Suzhou Zelgen Biopharmaceuticals Co Ltd?
Write Note

Suzhou Zelgen Biopharmaceuticals Co Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Suzhou Zelgen Biopharmaceuticals Co Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Gross Profit
ÂĄ357.2m
CAGR 3-Years
135%
CAGR 5-Years
285%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Gross Profit
ÂĄ14.7B
CAGR 3-Years
108%
CAGR 5-Years
67%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Gross Profit
ÂĄ4.5B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Gross Profit
ÂĄ3.3B
CAGR 3-Years
21%
CAGR 5-Years
19%
CAGR 10-Years
22%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Gross Profit
ÂĄ11.7B
CAGR 3-Years
3%
CAGR 5-Years
26%
CAGR 10-Years
38%
Imeik Technology Development Co Ltd
SZSE:300896
Gross Profit
ÂĄ2.7B
CAGR 3-Years
61%
CAGR 5-Years
57%
CAGR 10-Years
N/A
No Stocks Found

Suzhou Zelgen Biopharmaceuticals Co Ltd
Glance View

Market Cap
17B CNY
Industry
Biotechnology

Suzhou Zelgen Biopharmaceuticals Co., Ltd. engages in the innovation, research, development, manufacturing, and commercialization of new medications. The company is headquartered in Suzhou, Jiangsu and currently employs 688 full-time employees. The company went IPO on 2020-01-23. The firm's main technology platforms include precision small molecule drugs R & D and industrialization platform and complex recombinant protein drug development and industrialization platform. The firm's R & D product pipelines include Donafenib, Recombinant human thrombin for topical use, Jaktinib hydrochloride tablets, Alkotinib, Recombinant human thyroid stimulating hormone for injection, Jaktinib hydrochloride cream, ZG5266, ZG0588, ZG170607, double Specific antibodies ZG005 and ZG006. The firm also provides R & D and clinical trial drug production and processing services. The firm operates its businesses primarily in Mainland China.

Intrinsic Value
57.58 CNY
Overvaluation 10%
Intrinsic Value
Price

See Also

What is Suzhou Zelgen Biopharmaceuticals Co Ltd's Gross Profit?
Gross Profit
357.2m CNY

Based on the financial report for Dec 31, 2023, Suzhou Zelgen Biopharmaceuticals Co Ltd's Gross Profit amounts to 357.2m CNY.

What is Suzhou Zelgen Biopharmaceuticals Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
285%

Over the last year, the Gross Profit growth was 29%. The average annual Gross Profit growth rates for Suzhou Zelgen Biopharmaceuticals Co Ltd have been 135% over the past three years , 285% over the past five years .

Back to Top